Phase II/III, multicentre, open-label, randomised study comparing autologous intravesical macrophage cell therapy (Bexidem) to intravesical Bacillus Calmette-Guerin (BCG) therapy in patients with superficial papillary bladder cancer who have undergone complete transurethral resection.

Trial Profile

Phase II/III, multicentre, open-label, randomised study comparing autologous intravesical macrophage cell therapy (Bexidem) to intravesical Bacillus Calmette-Guerin (BCG) therapy in patients with superficial papillary bladder cancer who have undergone complete transurethral resection.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs BCG; IDM 2
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors IDM Pharma
  • Most Recent Events

    • 03 Jun 2009 Status changed from active, no longer recruiting to completed.
    • 28 May 2009 Investigational drug (BCG), planned number of patients (138), official title, primary outcomes, actual start date (25 Jun 2004) and trial locations identified as reported by ISRCTN: Current Controlled Trials.
    • 28 May 2009 Actual end date (16 Mar 2007) added as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top